New data presented at the 2021 Digestive Disease Week has reported that Cologuard (mt-sDNA) provided the greatest reduction in CRC incidence versus annual faecal immunochemical test (FIT) and annual faecal occult blood test (FOBT) in a representative Medicare population.
In the presentation, ‘Cost-Effectiveness of Stool-Based colorectal Cancer Screening Using Reported Real-World Adherence Rates in a Medicare Population’ (Abstract Number: Su053), the researchers used the CRC-AIM microsimulation modelling platform to estimate the cost-effectiveness of stool-based screening strategies using test-specific, real-world adherence data. The analysis found that Cologuard was cost effective and resulted in a greater reduction in CRC incidence and mortality versus FIT and FOBT.
In an additional oral presentation from the New Hampshire Colonoscopy Registry that compared FIT, Cologuard, or screening colonoscopy, ‘Comparison of Colonoscopy Findings in Patients with Preceding FIT Positive and mt-sDNA Positive Tests to Patients Having Colonoscopy Only: Data From the New Hampshire Colonoscopy Registry’ (Abstract Number: 886), after follow-up colonoscopy, 1.7% of patients with a positive Cologuard test, 1.6% of patients with positive FIT and 0.3% of patients who underwent screening colonoscopy had adenocarcinoma/colorectal cancer. At follow-up colonoscopy, Cologuard tests were more likely to predict neoplasia than either FIT positivity or screening colonoscopy, largely due to an increased yield of serrated polyps.